The timeline of nanobody development reflects a steady series of innovations. In 2001, the term "nanobody" was introduced by ...

Alzheimer's drug shows long-term benefits in behavior and cognition. EU approval of Blarcamesine could boost its market value ...

New data show that lecanemab is well tolerated outside of clinical trial setting, with expected and manageable side effects.

That non-statistically significant numerical advantage was the pattern for almost all the study's secondary endpoints – including other scales measuring cognitive function (CDR-SB and MMSE ...

The results come from a cohort of patients with three years of follow-up in the pivotal Clarity AD trial of anti-amyloid antibody Leqembi ... a -0.95 decline on the CDR-SB cognition rating ...

An electrochemical sensor designed to address a global health issue that particularly impacts people in the Middle East and ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 ...

The FDA has approved Emrelis to treat adults with locally advanced or metastatic NSCLC with high c-Met protein overexpression.